Search for a command to run...
<h3>Background and Importance</h3> Given the poor compliance with psychotropic treatments, in 2023 the French PIC (Psychiatric Information Communication) network published the first version of the lithium notebook for patients taking lithium, to improve their knowledge about the drug and reduce the risk of relapse. <h3>Aim and Objectives</h3> The introduction of lithium pharmaceutical consultations in our establishment aims to assess the relevance of involving the clinical pharmacist in the care pathway of patients. This allowed us to establish an overview of the information provided during the prescription process. <h3>Material and Methods</h3> Pharmaceutical consultations were offered to all accessible patients on lithium (whether lithium initiation or not), regardless of age or indication, except those in intensive care units. A summary of the knowledge acquired during the consultation or already assimilated by the patient was completed after each consultation, focusing on six main areas of knowledge (what to do in case of missed doses, adverse effects, pregnancy and contraception, drug interactions, signs of overdose and risk situations, and therapeutic follow-up). <h3>Results</h3> 15 patients (sex ratio 1:1, average age 45.6 years) have been benefited from lithium pharmaceutical consultations. 40% (n=6) of consultations were conducted as part of treatment initiation and for 1 patient as part of lithium reintroduction. 100% of patients were taking Lithium LP 400mg, indicated in bipolar disorder. The mean consultation lasted 42.5 minutes. 100% of patients were informed for the first time during the consultation of the signs of overdose and risk situations, 86.6% (n=13) about drug interactions and about adverse effects and what to do if they miss a dose for 80% (n=12) (with respectively 13.3% (n=2) and 6.6% (n=1) of patients previously informed). Therapeutic follow-up is well understood : 73.3% of patients were previously informed. The four patients informed for the first time during the pharmaceutical consultation were those who had just started lithium treatment. All patients received the lithium notebook as a complement, and a consultation report was filed in the Electronic Medical Record. <h3>Conclusion and Relevance</h3> The information provided to patients at the time of prescription appears to be insufficient. Pharmaceutical consultations seem to play a crucial role. These consultations often provide an opportunity for patients to ask questions. <h3>Conflict of Interest</h3> No conflict of interest